Annual report pursuant to Section 13 and 15(d)

Note 3 - Discontinued Operations - Discontinued Operations (Details)

v3.19.1
Note 3 - Discontinued Operations - Discontinued Operations (Details) - USD ($)
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Accrued liabilities $ 7,092
Liabilities associated with discontinued operations, current 7,092
Lymphoseek sales revenue 2,917,213
Cost of goods sold 364,192
Gross profit 2,553,021
Operating expenses of discontinued operation:    
Research and development (1,835) 383,446
Selling, general and administrative 961,873
Total operating expenses (1,835) 1,345,319
Income from discontinued operations 1,835 1,207,702
Interest expense (1,706,491)
Income (loss) before income taxes 1,835 (498,789)
(Provision for) benefit from income taxes (385) 8,031
Income (loss) from discontinued operations $ 1,449 $ (490,758)